W. Dokter

发表

Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor

W. Alkema, W. Fleuren, J. Tuckermann, 2010, BMC Genomics.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

R. Ubink, M. Wuhrer, W. Dokter, 2016, mAbs.

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

R. Ubink, M. Eppink, P. Beusker, 2014, Molecular Cancer Therapeutics.

Synthesis and Evaluation of a Series of Long‐Acting Glucagon‐Like Peptide‐1 (GLP‐1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes

N. Irwin, P. Flatt, S. Patterson, 2015, ChemMedChem.

Drug Design Approaches to Manipulate the Agonist-Antagonist Equilibrium in Steroid Receptors

J. D. Vlieg, W. Dokter, P. Hermkens, 2012 .

Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

R. Heine, A. Mari, M. Diamant, 2010, European journal of endocrinology.

Prednisolone induces the Wnt signalling pathway in 3T3-L1 adipocytes

W. Alkema, W. Fleuren, D. Ouwens, 2013, Archives of physiology and biochemistry.

Chronic prednisolone treatment reduces hepatic insulin sensitivity while perturbing the fed-to-fasting transition in mice.

A. Grefhorst, T. V. van Dijk, D. Reijngoud, 2010, Endocrinology.

A platform for the generation of site-specific antibody-drug conjugates that allows for selective reduction of engineered cysteines.

R. Ubink, P. Beusker, M. Blomenröhr, 2020, Bioconjugate chemistry.

Identification of gene signatures for prednisolone-induced metabolic dysfunction in collagen-induced arthritic mice.

W. Fleuren, E. Toonen, W. Dokter, 2014, Pharmacogenomics.

Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

R. Ubink, Kim Berentsen, W. Dokter, 2018, Molecular Cancer Therapeutics.

Pharmacological characterization and antidiabetic activity of a long‐acting glucagon‐like peptide‐1 analogue conjugated to an antithrombin III‐binding pentasaccharide

N. Irwin, S. Patterson, W. Dokter, 2015, Diabetes, obesity & metabolism.

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

R. Ubink, P. Beusker, W. Dokter, 2015, Molecular Cancer Therapeutics.

Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.

D. Auld, J. van der Louw, M. Webb, 2006, Bioorganic & medicinal chemistry letters.

Functional replacement of murine CXCR2 by its human homologue in the development of atherosclerosis in LDLR knockout mice.

M. Smit, W. Dokter, M. Rooseboom, 2007, Biological & pharmaceutical bulletin.

Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance

L. Joosten, M. Netea, C. Tack, 2016, Molecular medicine.

Conjugation of ATIII‐Binding Pentasaccharides to Extend the Half‐Life of Proteins: Long‐Acting Insulin

M. Honing, M. Eppink, M. Smit, 2008, ChemMedChem.

Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling

Age K Smilde, Thomas Hankemeier, Ton Rullmann, 2012, Genome Medicine.

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

R. Ubink, P. Beusker, W. Dokter, 2015, Molecular pharmaceutics.

Human CXCR2 (hCXCR2) takes over functionalities of its murine homolog in hCXCR2 knockin mice

M. Smit, M. Krajnc-Franken, W. Dokter, 2005, European journal of immunology.

An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy

K. Kok, B. Kroesen, M. Ruiters, 1999, Cancer Immunology, Immunotherapy.

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

J. Arribas, V. Peg, W. Dokter, 2020, Cancers.

Prednisolone-induced changes in gene-expression profiles in healthy volunteers.

W. Alkema, W. Fleuren, E. Toonen, 2011, Pharmacogenomics.

The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.

H. Hollema, M. Harmsen, B. Kroesen, 2001, Cancer research.

New Model to Study Carcinoma-directed Immunotherapy Epithelial-specific Expression of EGP-2 in Transgenic Mice : A The Epithelial Glycoprotein 2 ( EGP-2 ) Promoter-driven Updated

H. Hollema, M. Harmsen, B. Kroesen, 2001 .

Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines

P. Terpstra, M. Harmsen, B. Kroesen, 2004, Cancer Gene Therapy.

Glucose Kinetics in the Collagen-Induced Arthritis Model: An All-in-One Model to Assess Both Efficacy and Metabolic Side Effects of Glucocorticoids

A. Grefhorst, T. V. van Dijk, A. Bleeker, 2014, PloS one.

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas

A. Italiano, W. Dokter, N. Penel, 2021, Cancers.

Org 214007-0: A Novel Non-Steroidal Selective Glucocorticoid Receptor Modulator with Full Anti-Inflammatory Properties and Improved Therapeutic Index

R. McGuire, W. Alkema, A. Grefhorst, 2012, PloS one.

Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells.

W. Alkema, D. Ouwens, M. Diamant, 2011, Cellular signalling.

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

A. Pandiella, J. Arribas, W. Dokter, 2022, Cancer research.

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

R. Ubink, T. K. van den Berg, M. Paradé, 2023, Journal for ImmunoTherapy of Cancer.

Chronic prednisolone treatment aggravates hyperglycemia in mice fed a high-fat diet but does not worsen dietary fat-induced insulin resistance.

A. Grefhorst, T. V. van Dijk, D. Reijngoud, 2012, Endocrinology.

Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance

L. Joosten, M. Netea, C. Tack, 2016, Molecular Medicine.